Spots Global Cancer Trial Database for Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas

Official Title: Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)

Study ID: NCT02364024

Conditions

Metastatic Colorectal Cancer

Interventions

Study Description

Brief Summary: The purpose of this study is to confirm that linear quantification of CD3+ cells is a prognostic biomarker in localized colorectal carcinomas.

Detailed Description: Adult patients of both gender who have underwent surgical resection of stage III colorectal carcinoma and randomised to receive a chemotherapy FOLFOX or FOLFOX + Cetuximab in the PETACC8 trial.